Sichuan Meida’s Phentolamine Gains Priority Review for Pheochromocytoma Treatment
The Center for Drug Evaluation (CDE) website indicates that Sichuan Meida Kangjiale Pharmaceutical Co., Ltd’s...
Drug
Mabwell’s 6MW3511 Accepted by NMPA for Advanced Solid Tumor Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that a clinical trial filing for...
Takeda’s Obizur Accepted by China’s NMPA for Acquired Hemophilia A Treatment
Takeda Pharmaceutical Co., Ltd’s (NYSE: TAK, TYO: 4502) China unit announced that a New Drug...
Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...
Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...
Suzhou Zelgen’s JAK Inhibitor Jacktinib Gets NMPA Green Light for COVID-19 Trial
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval...
Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...
Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...
Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...
Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...
Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...
Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...
Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...
Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...
Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
BeiGene’s Brukinsa Faces Three-Month FDA Approval Delay for CLL/SLL Indication
China-based biotech company BeiGene Inc. (Nasdaq: BGNE) will experience a three-month delay in its pursuit...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...
Innovent Biologics Receives BPOM Approval for Bevagen in Indonesia
China-based Innovent Biologics Inc. (HKG: 1801) has announced receiving indication approvals from Indonesia’s Badan Pengawas...